Imaging biomarkers are needed for assessing treatment response in hepatocellular carcinoma (HCC). We evaluated BOLD MRI with hyperoxic challenge in an orthotopic rodent model of HCC for animals treated with the widely used kinase inhibitor sorafenib. A reduction in ΔT2* in tumor and background liver was exhibited for rats treated with sorafenib relative to untreated controls, while no significant change was observed in skeletal muscle. These results demonstrate that BOLD MRI could be a useful tool for detecting treatment effects in HCC.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords